WOUND HEALING PROMOTION IN RATS TREATED WITH EGF IS DOSE DEPENDENT

Jorge Berlanga,1 Evelio Moreira,2 Luis C Pérez,1 Eduardo Boix,2 Tania González1 and Pedro López-Saura1
1Centro de Ingeniería Genética y Biotecnología, Apartado postal 6162, Ciudad de La Habana, Cuba.
2Departamento de Anatomía Patológica, Hospital Pediátrico "Juan Manuel Márquez", Ciudad de La Habana, Cuba.

The relationship between Epidermal Growth Factor (EGF) dose and healing activity, has not been established when EGF is formulated as a semisolid cream. In order to address this question, groups of 18 experimentally wounded Sprague Dawley rats were assigned to: A - untreated or treated with B, B - hydrophilic vehicle only, C - 0.5 μg recombinant human EGF (rh-EGF)/g; D - 5 μg rh-EGF/g and E - 10 μg rh-EGF/g of hydrophilic vehicle using a full-thickness skin wound model. After seven days, re-epithelization, percent of animals per group with re-epithelized lesions to more than 90 %, non-epithelized space between edges, and wound contraction level were assayed. The relationship between doses, inflammatory infiltrate and the fibrovascular reaction were also evaluated. Re-epithelization was significantly enhanced in groups D and E compared to A, B and C. Forty seven percent of animals in group E showed re-epitelization of lesions to more than 90 % compared to groups A, B and C (p < 0.05). With respect to wound contraction and the amounts of non-re-epithelized space between edges, groups D and E exhibited similar responses, which were significantly improved with respect to groups A, B or C. Inflammatory infiltrate was significantly reduced in groups D and E, and showed a highest fibrovascular reaction compared to groups A, B and C.

Key words: re-epithelization, wound contraction

Biotecnología Aplicada 1996;13:181-185

RESUMEN

Actualmente no se dispone de elementos experimentales, que avalen la utilización de determinadas dosis de Factor de Crecimiento Epidérmico (EGF) en formulaciones semisólidas tópicas para estimular la cicatrización. Para realizar esto, se utilizaron grupos de 18 ratas hembras Sprague Dawley lesionadas experimentalemente, asignadas a: A - grupo no tratado o tratado con B, B - vehículo hidrófugo, C - 0.5 μg de EGF humano recombinante (rh-EGF)/g; D - 5 μg rh-EGF/g y E - 10 μg rh-EGF/g de vehículo. Al séptimo tratamiento, las lesiones fueron resecadas y procesadas para evaluar los siguientes aspectos: reepitelización, porcentaje de animales por grupo con lesiones epitelizadas a más de 90 %, espacio no epitelizado y nivel de contracción de la herida. También se estudió la relación entre dosis, la intensidad del infiltrado inflamatorio y la respuesta fibrovascular en cada grupo. La reepitelización fue significativamente superior en los grupos D y E comparados con los grupos A, B y C. El 47 % de los animales en el grupo E mostró más del 90 % de reepitelización comparado con los grupos A, B y C (p < 0.05). Los grupos D y E mostraron respuestas similares en cuanto a contracción de herida y espacio reepitelizado entre los bordes. La respuesta inflamatoria en los grupos D y E fue significativamente menor y se constató una respuesta fibroplásica superior a los grupos A, B y C.

Palabras claves: reepitelización, contracción de herida

Introduction

Wound healing is a localized process which involves inflammation, wound cell migration and mitosis, neovascularization and regeneration of the extracellular matrix. Recent evidence suggests that these phenomena may be regulated by peptide growth factors through autocrine and paracrine mechanisms (1). Among these growth factors, the healing promoting effect of the Epidermal Growth Factor (EGF) has been reported (2).

Earlier studies demonstrated its to induce epidermal cell maturation and enhanced mitosis (3).

Other evidence suggests that this molecule may act as an epidermal migration factor rather than a simple mitogen in healing wounds (4). Direct application of EGF to different wound models in vivo has shown significantly enhanced rates of epithelial regeneration and increased wound tensile strength (5).

Buckley, et al. (6) were the first to report that sustained and slow release of critical concentrations of EGF into the wound site, is an important prerequisite to achieve significant increases in wound granulation tissue. They also confirmed that the


1 Correspondence Author

181
number of persistently occupied receptors depends upon specific ligand concentrations, which determines the degree of mitogenic stimulation. Formulation of EGF in cream vehicles has been claimed to promote this slow release of the factor to the damaged area (2).

Despite the many observations in vitro, and the evidence derived from in vivo studies, the role played by growth factors during wound repair is not clear. This is in part the result of the limited knowledge regarding the effective concentrations which promote an optimal healing response, and the difficulty for delivering these growth factors and quantifying the responses to them in vivo (6, 7).

To date, the healing effect exerted by different concentrations of rh-EGF, as a topical cream formulation has not been defined. In this paper we show that re-epithelization and dermal matrix reconstitution are independent events and responsive to EGF treatment in a concentration-dependent fashion.

**Materials and Methods**

**Animals**

Ninety female Sprague Dawley rats, (CENPALAB, Cuba) with 250 g average weight were kept in metabolic cages (IFACREDO 0.82 - 426) under controlled environmental conditions with free access to water and food.

**EGF and Formulations**

Recombinant human EGF was produced in *Saccharomyces cerevisiae* at the Center for Genetic Engineering and Biotechnology, Havana. The product was obtained with more than 95 % purity (8). It was formulated at 10, 5, and 0.5 µg EGF per gram of hydrophilic cream. EGF biological activity was assessed by a receptor-binding assay (9). Concentrations for formulation were determined by an ELISA method (10).

**Wound Model**

Nine millimeters-diameter, full-thickness skin wounds were practiced on the external side of the right upper hind limb with a skin biotome (Acu Punch, Acuderm Inc, USA) in aseptic conditions and under sufficient anesthetic degree induced with diethyl ether mask.

Rats were distributed among five experimental groups of 18 animals each.

- **Group A:** untreated
- **Group B:** treated with hydrophilic cream only
- **Group C:** treated with hydrophilic cream containing EGF at 0.5 µg/g
- **Group D:** treated with hydrophilic cream containing EGF at 5 µg/g
- **Group E:** treated with hydrophilic cream containing EGF at 10 µg/g

Treatment was initiated immediately after creating the wounds and continued daily up to the 7th day, when the experiment was stopped according to previous studies on the model (6, 7).

**Sample Processing**

Ulcera area and a portion of surrounding tissue were excised using surgical scissors and fixed in 10% buffered formalin. Tissue samples were paraffin-embedded and sectioned at 5 µm, from hematoxilin-eosin, PAS/Acinian Blue, and van Giessen stainings.

Samples were blindly evaluated by different pathologists (Department of Pathology, Pediatric Hospital "Juan M. Marquez") using a sham identification label. Samples consisted of a 3 mm-thick slice obtained from the center of the ulcer by a sagittal cut.

**Wound Healing Criteria**

- Re-epithelization (ReE) was determined by the sum of the distances from the edges of the wound to each epithelial margin.
- Non-epithelial space between edges (SBE) was determined by measuring the non-epithelialized area between the growing edges.

All measurements were made with morphometric scale eyepieces (Olympus) and a constant magnification of 10x. Figure 1 illustrates how measurements were done and how slices were taken for microscopic examination.

- Wound contraction level (WCL) was calculated as:

\[ WCL = 9 - (\text{Total ReE + SBE}) \]

Results are expressed in mm.

- Percent of epithelialized area (PEA), was calculated as:

\[ \text{PEA} = \frac{1 - (\text{SBE})^2}{81} \times 100 \]

**Figure 1.** Front (A) and lateral (B) diagrams of the wounds. The box (3 mm diameter) represents the slice taken for histological examination. Micrometric measurements were: re-epithelialized area (a and d); distance between epithelialized borders (b); total initial wound diameter (t = 9 mm).


182

Biotecnologia Aplicada 1996; Vol. 13, No. 3
Histologic Grading System
Inflammatory infiltrate was classified according to its intensity using the following criteria:
- Mild: a limited number of inflammatory cells spread out in the healing tissue, without focal concentration.
- Intense: an abundant number of inflammatory cells with focal or disperse pattern of distribution.

Fibro-vascular reaction was classified as follows:
- Mild: a granulation tissue with incipient formation of collagen fibers, vertically distributed, without forming an organized meshwork of fibers. An abundant number of active vascular sprouts is considered, in addition to an intense inflammatory reaction.
- Intense: a large amount of thicker collagen fibers in horizontal arrangement, forming a woven meshwork of fiber bundles. Positivity to van Gieson was considered.

Statistical Analysis
Non-parametric statistic tests were preferred in order to avoid assumptions on the normal distribution of the data. These were processed by Mann-Whitney U and chi-square tests. Statistical significance was established for p ≤ 0.05.

Results

Re-epithelization (Re)
Animals from group E, treated with the highest dose level of EGF (10 μg/g) exhibited a significantly enhanced rate of re-epithelization with respect to groups A (p = 0.001), B (p = 0.05) and C (p = 0.011).

The effect exerted by the second dose level (group D) was similar to that seen in group E. Epithelial responses registered for group D, showed a strong tendency to be significantly higher than the value observed in group C (p = 0.054). Its enhanced re-epithelization was also noticed when compared to values recorded in groups, A (p = 0.006) and B (p = 0.043). The 0.5 μg EGF dose did not stimulate re-epithelization. The responses exhibited by this treatment group did not differ to those of groups A and B, (Figure 2).

In group E, 47.1 % (eight animals), lesions were re-epithelized to more than 90 %. This was significantly higher with respect to the number of animals of groups A, 6 % (p = 0.025) and B, 12 % (p = 0.01). The next significant result was obtained in group D with seven animals, (41.1 %) which differed from group A, 6 % (p = 0.05). Animals from group C reflected no improvement with respect to A and B (Table 1).

Non-epithelized Space Between Edges (SBE)
The results indicate that treatments of groups D and E elicited a similar effect on the animals. It is noticeable that group E showed a better result solely with respect to group A (p = 0.011). However group D expressed significantly smaller values of SBE with respect to those calculated for groups A

Table 1. Animals with more than 90 % of epithelized area, fibrovascular reaction and inflammatory infiltrate in the different groups: untreated (A), hydrophilic vehicle (B) and EGF at 0.5 μg/g (C), 5 μg/g (D) or 10 μg/g (E). One biopsy sample from groups D and E was not useful for examination.

<table>
<thead>
<tr>
<th>Group</th>
<th>Animals with &gt; 90 % epithelization</th>
<th>Fibrovascular reaction</th>
<th>Inflammatory infiltrate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N/total</td>
<td>%</td>
<td>Mild</td>
</tr>
<tr>
<td>A</td>
<td>1/18</td>
<td>5.6</td>
<td>14</td>
</tr>
<tr>
<td>B</td>
<td>2/17</td>
<td>11.8</td>
<td>13</td>
</tr>
<tr>
<td>C</td>
<td>5/17</td>
<td>29.4</td>
<td>14</td>
</tr>
<tr>
<td>D</td>
<td>7/18</td>
<td>41.1*</td>
<td>5</td>
</tr>
<tr>
<td>E</td>
<td>8/18</td>
<td>47.1*</td>
<td>5</td>
</tr>
</tbody>
</table>

* significant difference with groups A and B. For details and p values see text. *(p < 0.05)
Discussion

One of the first biological effects of EGF noticed by Cohen was the hypertrophy of the epidermis which occurred in mice after repeated injections with EGF (11).

Barrandon and Green (4) suggested that EGF exerts an effect on the epidermis to speed up wound closure. Afterwards, several attempts were made to demonstrate an effect of EGF on healing skin wounds in vivo, but controversy still exists about the virtues of EGF in accelerating wound healing (12). One of the possible explanations for the ineffectiveness of EGF in in vivo trials, may be that optimal doses and application schedule have yet to be determined (7).

Since wound healing is a process of overlapping biological events including inflammation and mesenchymal and epithelial cell migration, we assessed how different EGF concentrations in a topical formulation could influence on each of these processes.

Figure 5. Specimen from group E (10 µg EGF/g), showing a portion of mature neoeipidermis, and a well organized collagen matrix, at 7th day of treatment. Note a fragment of consolidated and rejected scab above the neoeipidermis. Similar findings were obtained from group D. PAS/Aloian Blue x 10.

Re-epithelization of a wound begins within hours after injury by the migration of cells from the wound margin out across the defect (13). These cells exhibit a specific phenotype and express a large number of EGF/TGF-alpha receptors. EGF is a well-documented agent in promoting epithelial-cell proliferation, keratinization and increasing the thickness of the epidermis (11).

In this study, re-epithelization was significantly stimulated by EGF at concentrations of 10 and 5 μg/g, but not at 0.5 μg/g of vehicle. Although groups D and E did not show statistical difference, a trend is noticed showing an improved wound resurfacing with the highest dose level treatment.

Others have also reported a dose-dependent re-epithelizing effect in the range of 100 ng-10 μg/mL, but in such experiment, a different vehicle for the formulation was used, therefore the in situ EGF bioavailability cannot be compared (14).

Previous studies have shown that exogenous EGF might act, not only on the epidermal component of a cutaneous wound, but also enhancing collagen matrix synthesis and contraction which are associated to its mitogenic and chemotactic properties on normal dermal fibroblasts and for granulation tissue-derived fibroblasts (15, 16). EGF and TGF-alpha act also as angiogenic factors, stimulating blood vessel sprouting in granulation tissue (17).

Wound closure occurs from the margins of the wound and the acting contractile force derives mainly from a differentiated cell in the granulation tissue: the myofibroblast (18). As part of the dermal-mediated response, we evaluated the wound contraction level (WCL) on each experimental group. This parameter was influenced by each of the EGF treatments at 10, 5 and 0.5 μg EGF/g of vehicle. It is notorious that the largest relative response of WCL was observed in group D, and that groups E and C, were only different to A (untreated control).

Previous studies have shown that EGF is capable of inducing collagen-lattice contraction in vitro (19) as well as in vivo (16). The reduction of the SBE might be due to wound contraction or to a larger epithelial outgrowth from the edges of the ulcers.

Both phenomena have proved to be significantly stimulated by 5 and 10 μg/g EGF doses in this experiment.

Nevertheless, it is interesting to observe that re-epithelization seemed more enhanced by the 10 μg/g dose rather than by the 5 μg/g EGF dose; the latter however, elicited a greater stimulating effect on the dermal-mediated response, such as collagenization and wound contraction. Albeit, the lowest EGF dose, did not show to exert any effect on the epidermal regeneration, it was capable of stimulating dermal contraction. This phenomenon of differential sensitivity to EGF, showed by keratinocytes and dermal fibroblasts, could be in relation to the number of constantly occupied receptors, which ultimately regulate a cellular response.

In this context, dose-dependent increase in the cellularity and thickness of the neodermis has also been invoked as a mechanism of action of topical EGF formulations (20). Mustoe, et al. (21), showed that EGF concentrations higher or lower than an optimal dose may be less effective in achieving a clinically acceptable healing improvement.

The environment of healing wounds is rich in growth factors, which coordinately stimulates several steps by virtue of a precisely regulated interplay among them. Experiments have demonstrated that imbalances in the concentration of one polypeptide growth factor may lead to down-regulation of critical functions of the exposed cells (14, 22, 23).

In our trauma model of controlled infection, groups D and E, exhibited a better healing response and were less inflamed; whereas the other groups (A, B, C) were intensely infiltrated with round inflammatory cells.

Despite that no direct effect on the wound inflammation intensity, neither on the infiltrating specific-cell stripe, have been linked to EGF treatments (23); it is notorious that groups treated with larger doses are less inflamed. Although inflammatory cells do not express EGF-receptor (13), a modification on the local pulses of other cytokines, may arise as a consequence of the EGF topical treatment.

The results presented here show that, re-epithelization, dermis reconstitution and wound contraction, are significantly stimulated by EGF- specific concentrations. On the other hand, it seemed that epidermis and dermis-mediated events exhibit particular sensitivity to a single EGF dose, which is capable of eliciting a more pronounced tissue response.

Acknowledgements

Authors are very grateful to Dr. Edward E. Tredget (Director of the Plastic Surgery Research Lab of the University of Alberta) for his critical advises, and to Jesús Seoane for his photographic assistance.